Vascarta Inc. has initiated a Phase 1 clinical study for VAS-101, a transdermal curcumin gel designed to provide non-opioid pain relief for sickle cell disease (SCD). Conducted by the Foundation for Sickle Cell Disease Research in Florida under Dr. Gershwin T. Blyden’s supervision, the trial will evaluate the safety and therapeutic potential of VAS-101 in improving blood flow, reducing inflammation, and alleviating pain. Dr. Lanetta Bronté-Hall of FSCDR emphasized, “Pain is one of the most disruptive aspects of SCD, and innovative solutions like VAS-101 are essential to addressing this unmet need.”

VAS-101 represents a novel approach, leveraging curcumin’s anti-inflammatory and anti-sickling properties through a patented delivery system that enhances bioavailability. Early preclinical studies, including findings published in PNAS Nexus, suggest promise in stabilizing red blood cells and reducing neuroinflammation.

At OxyDial, we recognize the importance of expanding accessible, non-opioid therapies for SCD, particularly in underserved communities where pain management remains a critical challenge. If successful, VAS-101 could mark a significant step forward in improving the quality of life for patients.

Read more: https://www.prnewswire.com/news-releases/vascarta-commences-proof-of-concept-phase-1-clinical-study-of-vas-101-in-sickle-cell-disease-in-the-united-states-302428782.html

#SickleCellDisease #PainRelief #NonOpioid #SCDResearch #VAS101 #Hematology #OxyDial